Journal ArticleDOI
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E. Hynes,Heidi Lane +1 more
TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.Abstract:
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.read more
Citations
More filters
Journal ArticleDOI
Chimeric antigen receptor T cells: a novel therapy for solid tumors.
TL;DR: The preclinical and clinical progress of CAR-T cells targeting EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN), as well as the challenges forCAR-T cell therapy are summarized.
Journal ArticleDOI
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Genta Sawada,Genta Sawada,Atsushi Niida,Ryutaro Uchi,Hidenari Hirata,Teppei Shimamura,Yutaka Suzuki,Yuichi Shiraishi,Kenichi Chiba,Seiya Imoto,Yusuke Takahashi,Yusuke Takahashi,Takeshi Iwaya,Tomoya Sudo,Tomoatsu Hayashi,Hiroki Takai,Yoshihiro Kawasaki,Takashi Matsukawa,Hidetoshi Eguchi,Keishi Sugimachi,Fumiaki Tanaka,Hiromichi Suzuki,Ken Yamamoto,Hideshi Ishii,Makiko Shimizu,Hiroshi Yamazaki,Makoto Yamazaki,Yuji Tachimori,Yoshiaki Kajiyama,Shoji Natsugoe,Hiromasa Fujita,Ken-ichi Mafune,Yoichi Tanaka,David P. Kelsell,Claire A. Scott,Shoji Tsuji,Shinichi Yachida,Tatsuhiro Shibata,Sumio Sugano,Yuichiro Doki,Tetsu Akiyama,Hiroyuki Aburatani,Seishi Ogawa,Satoru Miyano,Masaki Mori,Koshi Mimori +45 more
TL;DR: A large-scale genomic analysis of ESCCs from patients in Japan determined the mutational landscape of this cancer and associated environmental and genetic factors with base substitution patterns of somatic mutations and provide a registry of genes and pathways that are disrupted in ES CCs.
Journal ArticleDOI
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
TL;DR: The current state of the art research for targeted therapy in NSCLC is outlined, with Aberrations in other key signaling pathways and molecules, such as RAS/RAF/MEK, PI3K/AKT/mTOR, or MET kinase, have been identified as crucial targets, especially in resistant patients.
Journal ArticleDOI
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
TL;DR: Machine learning analysis applied to the Cancer Cell Line Encyclopedia database identified expression of AXL, the gene that encodes the epithelial-to-mesenchymal transition (EMT)–associated receptor tyrosine kinase (RTK) A XL, as exceptionally predictive of lack of response to ErbB family receptor–targeted inhibitors.
Journal ArticleDOI
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Panomwat Amornphimoltham,Vyomesh Patel,Akrit Sodhi,Nikolaos G. Nikitakis,John J. Sauk,Edward A. Sausville,Alfredo A. Molinolo,J. Silvio Gutkind +7 more
TL;DR: The Akt-mTOR pathway is identified as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNS CC.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more